Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 5/20 | 0.39 |
| ▸ | ABL1 | P00519 | 11/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9068603 | 0.93 | ABL1 (0.40) | ABL1 | |
| SCHEMBL8997388 | 0.85 | ABL1 (0.41) | EZH2ABL1 | |
| SCHEMBL9068612 | 0.83 | ABL1 (0.43) | ABL1 | |
| SCHEMBL8998567 | 0.83 | ABL1 (0.43) | ABL1PIK3CA | |
| SCHEMBL13953989 | 0.82 | AURKA (0.43) | ABL1MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL8999489 | 0.81 | ABL1 (0.44) | ABL1MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL13953891 | 0.81 | ABL1 (0.42) | ABL1 | |
| SCHEMBL12229494 | 0.81 | ABL1 (0.40) | ABL1MAPK1AURKB | |
| SCHEMBL9068495 | 0.81 | ABL1 (0.58) | ABL1 | |
| SCHEMBL9068458 | 0.80 | ABL1 (0.43) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188095-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-29 | — | — | US | disclosed |
| US-8034832-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090325935-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
| US-7495014-B2 | Gyrase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176771-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | EZH2 3533/4885ABL1 460/4885MAPK1 3610/4885 |
| US-20090325935-A1 | GYRASE INHIBITORS AND USES THEREOF | TOP1, TOP2A, TOP2B | EZH2 3454/4885ABL1 469/4885MAPK1 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.